CAN
SYRS

Claraphi Advisory Network’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Claraphi Advisory Network’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,800
Closed -$214K – 281
2018
Q3 		$214K Buy
1,800
+200
+13% +$23.2K 0.12% 227
2018
Q2 		$163K Buy
+1,600
New +$198K 0.11% 251

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Claraphi Advisory Network's SYRS Position: Q4 2018 in Review

Claraphi Advisory Network sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2018, closing a stake of 1,800 shares — an estimated $214K sold.

Claraphi Advisory Network first reported a position in SYRS in Q2 2018 and held it in 2 quarters. The position peaked at $214K in Q3 2018. 68 funds tracked by Wall St. Rank hold SYRS as of Q4 2018.

  • Claraphi Advisory Network reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Claraphi Advisory Network sold 1,800 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $214K.
  • Claraphi Advisory Network first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Claraphi Advisory Network's Syros Pharmaceuticals, Inc. Common Stock position peaked at $214K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Claraphi Advisory Network's 13F filing for Q4 2018, filed 12 Feb 2019.